Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
| ▸ | ACACA | Q13085 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 8/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 8/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 8/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.34 |
| ▸ | GABRP | O00591 | 3/20 | 0.34 |
| ▸ | GABRD | O14764 | 3/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.34 |
| ▸ | GABRE | P78334 | 3/20 | 0.34 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.34 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.34 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6982885 | 0.83 | CFTR (0.37) | SLC7A5GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL7471367 | 0.80 | KDM4E (0.40) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL27537755 | 0.78 | SLC7A5 (0.39) | SLC7A5LOXL2CYP2C9NR1H2ALDH1A1 | |
| SCHEMBL1018101 | 0.75 | SLC7A5 (0.40) | SLC7A5LOXL2NR1H2ALDH1A1RXRA | |
| SCHEMBL18681199 | 0.75 | LOXL2 (0.45) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9630611 | 0.73 | GABRP (0.42) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL20719561 | 0.72 | SLC7A5 (0.38) | SLC7A5GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL29619789 | 0.72 | DHODH (0.44) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL28965796 | 0.72 | DHODH (0.44) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL28983540 | 0.71 | CYP2C9 (0.46) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3447058-B1 | NOVEL BROAD-SPECTRUM BETA-LACTAMASE INHIBITOR | WUHAN VISION PHARMACEUTICAL TECH CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-10479805-B2 | Beta-lactamase inhibitor | WUHAN VISION PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-11-19 | — | — | US | disclosed |
| US-20190048027-A1 | BETA-LACTAMASE INHIBITOR | WUHAN VISION PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-02-14 | — | — | US | disclosed |
| CN-105801610-B | New-type wide-spectrum beta-lactamase inhibitor | 武汉维舜医药科技有限公司 | 2018-05-18 | — | — | CN | disclosed |
| CN-105801610-A | Novel broad-spectrum beta-lactamase inhibitor | 武汉维舜医药科技有限公司 | 2016-07-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048027-A1 | BETA-LACTAMASE INHIBITOR | ALPI, MGAM, LCT | SLC7A5 2227/4885ACACB 984/4885ACACA 1023/4885 |
| US-10479805-B2 | Beta-lactamase inhibitor | ALPI, MGAM, LCT | SLC7A5 2227/4885ACACB 984/4885ACACA 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.